Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03068780
Registration number
NCT03068780
Ethics application status
Date submitted
27/02/2017
Date registered
3/03/2017
Titles & IDs
Public title
Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa
Query!
Scientific title
Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Query!
Secondary ID [1]
0
0
2016-002066-32
Query!
Secondary ID [2]
0
0
BEB-13
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
EASE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Epidermolysis Bullosa
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Oleogel-S10
Treatment: Drugs - Control gel
Experimental: Oleogel-S10 -
Placebo comparator: Control Gel -
Treatment: Drugs: Oleogel-S10
10% birch bark extract in 90% sunflower oil
Treatment: Drugs: Control gel
Sunflower oil, Cera flava/yellow wax, and Carnauba wax (matched Oleogel-S10 in terms of texture and visual appearance)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Proportion of Patients With First Complete Closure of the EB Target Wound Within 45 Days of Treatment
Query!
Assessment method [1]
0
0
Proportion of subjects with first complete closure of the EB target wound (defined as EB partial-thickness wound of 10 cm2 to 50 cm2 in size and =21 days to \<9 months in age) in subjects with inherited EB (subtypes DEB, JEB, or Kindler EB) within 45 days of treatment with Oleogel-S10 compared to control gel based on clinical assessment by the investigator (the wound was rated as "closed" at first appearance of complete re-epithelialization without drainage).
Query!
Timepoint [1]
0
0
45±7 days
Query!
Secondary outcome [1]
0
0
Time to First Complete Closure of the EB Target Wound as Evidenced by Clinical Assessment Until Day 90 (D90) or End of Double-blind Phase (EDBP)
Query!
Assessment method [1]
0
0
The first key secondary endpoint was time to first complete closure of the EB target wound as evidenced by clinical assessment within 90 days or by EDBP, using a nonstratified log-rank test.
If the primary analysis of the primary efficacy endpoint showed superiority at the 5% significance level, hierarchical confirmatory testing of the 6 key secondary endpoints was to be performed.
Query!
Timepoint [1]
0
0
90±7 days
Query!
Secondary outcome [2]
0
0
Proportion of Patients With First Complete Closure of the EB Target Wound at D90 or EDBP Based on Clinical Assessment by the Investigator Until D90 or EDBP
Query!
Assessment method [2]
0
0
The second key secondary endpoint was the proportion of subjects with first complete closure of the EB target wound within 90 days of treatment or by EDBP based on clinical assessment by the investigator.
Query!
Timepoint [2]
0
0
90±7 days
Query!
Secondary outcome [3]
0
0
The Incidence of EB Target Wound Infection Between Baseline (DBP D0) and D90 or EDBP as Evidenced by Adverse Events (AEs) and/or Use of Topical and/or Systemic Antibiotics (Related to Wound Infection)
Query!
Assessment method [3]
0
0
The incidence of EB target wound infections between Baseline (DBP D0) and D90 or EDBP was assessed based on the total number of patients with an EB target wound infection, as evidenced by AEs and/or the use of topical and/or systemic antibiotics, and the total number of patients
Query!
Timepoint [3]
0
0
90±7 days
Query!
Secondary outcome [4]
0
0
The Maximum Severity of EB Target Wound Infection Between Baseline (DBP D0) and D90 or EDBP as Evidenced by AEs
Query!
Assessment method [4]
0
0
Target wound infections between baseline (DBP D0) and D90 or EDBP were assessed for maximum severity (maximum severity was evaluated if a subject had a wound infection event evidenced by AEs). \[Note: Here, 1 event less is recorded in the control gel group as for the previous secondary outcome measure, because only wound infections that were reported as AEs could be assessed for severity and were included in this analysis.\]
Query!
Timepoint [4]
0
0
90±7 days
Query!
Secondary outcome [5]
0
0
Change From Baseline (DBP D0) in Total Body Wound Burden as Evidenced by Clinical Assessment Using Section I (Assessment of the Skin Except for the Anogenital Region) of the 'EB Disease Activity and Scarring Index' (EBDASI), at D90 or EDBP
Query!
Assessment method [5]
0
0
The evaluation of total body wound burden (TBWB) was based on clinical assessment using Section I (Skin) of the Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). The EBDASI skin activity (blistering/erosions/crusting) was scored from 0 to 10 for each of 10 anatomical locations (excluding the anogenital and buttocks regions). Therefore, the total skin activity score (i.e., TBWB) could range from 0 to 100, with lower scores indicative of less wound burden. The change in TBWB was assessed from baseline (DBP D0) to D90 or EDBP.
Query!
Timepoint [5]
0
0
90±7 days
Query!
Secondary outcome [6]
0
0
Change From Baseline (DBP D0) in Itching Using the 'Itch Man Scale' in Patients = 4 Years and up to 13 Years of Age Before Wound Dressing Changes at D90 or EDBP
Query!
Assessment method [6]
0
0
Change from Baseline at D90 or EDBP on the Itch Man Scale in patients 4-13 years of age. The scale runs from 0 (comfortable, no itch) to 4 (itches most terribly, impossible to sit still, concentrate).
Query!
Timepoint [6]
0
0
90±7 days
Query!
Secondary outcome [7]
0
0
Change From Baseline (DBP D0) in Itching Using the 'Leuven Itch Scale' in Patients = 14 Years of Age Before Wound Dressing Changes at D90 or End of Double Blind Phase (EDBP)
Query!
Assessment method [7]
0
0
Change in Leuven Itch Scale (patients = 14 years of age) scores taken from two time points, Baseline and Day 90±7 \[End of Double Blind Phase (EDBP)\]. The Leuven Itch Scale measures six dimensions of the itch experience: Frequency Subscore (0 = Never to 100 = Always); Duration Subscore (0 = Between 0 and 30 minutes to 100 = More than 2 hours); Severity Subscore (0 = No itch to 100 = Worst possible itch); Consequences Subscore \[0 = Never to 100 = Always (lower score indicates less negative consequences from the itch)\]; Distress Subscore (0 = Not distressing at all to 100 = Very distressing); Surface Area Subscore (0-100, high values indicate more parts of the body are itching)
Query!
Timepoint [7]
0
0
90±7 days
Query!
Eligibility
Key inclusion criteria
* Male and female patients with the following subtypes of inherited EB: junctional EB (JEB), dystrophic EB (DEB), and Kindler EB aged =21 days
* Patients with an EB target wound (i.e., EB partial thickness wound of 10 cm² to 50 cm² in size aged =21 days and <9 months)
* Patient and/or his/her legal representative has/have been informed, has/have read and understood the patient information/informed consent form, and has/have given written informed consent
* Patient and/or his/her legal representative must be able and willing to follow study procedures and instructions
Query!
Minimum age
21
Days
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Patient has EB simplex
* EB target wound that is =9 months old or has clinical signs of local infection
* Use of systemic antibiotics for wound-related infections within 7 days prior to enrolment
* Administration of systemic or topical steroids (except for inhaled, ophthalmic or topical applications, such as budesonide suspension for oesophageal strictures [e.g., Pulmicort respules® 0.25 mg/2 mL or 0.5 mg/2 mL]) within 30 days before enrolment
* Immunosuppressive therapy or cytotoxic chemotherapy within 60 days prior to enrolment
* Patient has undergone stem cell transplant or gene therapy for the treatment of inherited EB
* Current and/or former malignancy including basal cell carcinomas and squamous cell carcinomas
* Enrolment in any interventional study or treated with any investigational drug for any disease within 4 weeks prior to study entry
* Factors present in the patient and/or his/her legal representative that could interfere with study compliance such as inability to attend scheduled study visits or compliance with home dressing changes
* Pregnant or nursing women and women of childbearing potential including postmenarchal female adolescents not willing to use an effective form of birth control with failure rates <1% per year (e.g., implant, injectable, combined oral contraceptive, intrauterine contraceptive device, sexual abstinence, vasectomised partner) during participation in the study (and at least 3 months thereafter)
* Patient is a member of the investigational team or his/her immediate family
* Patient lives in the same household as a study participant
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
29/03/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
27/05/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
223
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Sydney Children's Hospital - Sydney
Query!
Recruitment hospital [2]
0
0
Premier Specialists - Sydney
Query!
Recruitment hospital [3]
0
0
The Royal Melbourne Hospital - Parkville
Query!
Recruitment hospital [4]
0
0
Murdoch Childrens Research Institute Royal Children's Hospital - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2031 - Sydney
Query!
Recruitment postcode(s) [2]
0
0
2217 - Sydney
Query!
Recruitment postcode(s) [3]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [4]
0
0
3502 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Minnesota
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New York
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Ohio
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Pennsylvania
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
South Carolina
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
Argentina
Query!
State/province [10]
0
0
Buenos Aires
Query!
Country [11]
0
0
Austria
Query!
State/province [11]
0
0
Salzburg
Query!
Country [12]
0
0
Brazil
Query!
State/province [12]
0
0
Pernanbuco
Query!
Country [13]
0
0
Brazil
Query!
State/province [13]
0
0
Santa Catarina
Query!
Country [14]
0
0
Brazil
Query!
State/province [14]
0
0
São Paulo
Query!
Country [15]
0
0
Chile
Query!
State/province [15]
0
0
Santiago
Query!
Country [16]
0
0
Colombia
Query!
State/province [16]
0
0
DC
Query!
Country [17]
0
0
Czechia
Query!
State/province [17]
0
0
Brno
Query!
Country [18]
0
0
Denmark
Query!
State/province [18]
0
0
Aarhus
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Paris
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Toulouse
Query!
Country [21]
0
0
Georgia
Query!
State/province [21]
0
0
Tbilisi
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Freiburg im Breisgau
Query!
Country [23]
0
0
Germany
Query!
State/province [23]
0
0
Hannover
Query!
Country [24]
0
0
Greece
Query!
State/province [24]
0
0
Attiki
Query!
Country [25]
0
0
Hong Kong
Query!
State/province [25]
0
0
Hong Kong
Query!
Country [26]
0
0
Hungary
Query!
State/province [26]
0
0
Budapest
Query!
Country [27]
0
0
Ireland
Query!
State/province [27]
0
0
Dublin
Query!
Country [28]
0
0
Israel
Query!
State/province [28]
0
0
Tel Aviv
Query!
Country [29]
0
0
Italy
Query!
State/province [29]
0
0
Milan
Query!
Country [30]
0
0
Italy
Query!
State/province [30]
0
0
Roma
Query!
Country [31]
0
0
Romania
Query!
State/province [31]
0
0
Bucharest
Query!
Country [32]
0
0
Russian Federation
Query!
State/province [32]
0
0
Moscow
Query!
Country [33]
0
0
Serbia
Query!
State/province [33]
0
0
Belgrade
Query!
Country [34]
0
0
Singapore
Query!
State/province [34]
0
0
Singapore
Query!
Country [35]
0
0
Spain
Query!
State/province [35]
0
0
Barcelona
Query!
Country [36]
0
0
Spain
Query!
State/province [36]
0
0
Madrid
Query!
Country [37]
0
0
Spain
Query!
State/province [37]
0
0
Sevilla
Query!
Country [38]
0
0
Switzerland
Query!
State/province [38]
0
0
Bern
Query!
Country [39]
0
0
Ukraine
Query!
State/province [39]
0
0
Kyiv
Query!
Country [40]
0
0
United Kingdom
Query!
State/province [40]
0
0
Birmingham
Query!
Country [41]
0
0
United Kingdom
Query!
State/province [41]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Amryt Research Limited
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This was a Phase III, Efficacy and Safety Study of Oleogel-S10 in Participants with Inherited Epidermolysis Bullosa (EB). EB is a rare group of genetic skin fragility disorders characterised by blistering of the skin in response to minor injury. In most cases, onset of EB is at birth or shortly after. All participants affected by any type of EB share the main characteristic of repeatedly developing painful wounds that take days to months to heal. Current treatment of EB is primarily preventative and supportive including protection from mechanical forces by avoiding rubbing, early treatment of wounds to prevent infections, and protection of the wound with adequate non-adhesive dressings to enable healing. The active pharmaceutical ingredient in Oleogel-S10 is a refined birch bark extract, quantified to 72 to 88% betulin. This clinical study of Oleogel-S10 in patients with inherited EB has been carried out to investigate whether Oleogel-S10 is effective for treatment of EB wounds and safe for long-term use. Oleogel-S10 was compared to a control gel. The control gel matched Oleogel-S10 in terms of texture and visual appearance to allow for double-blinding. The packaging for Oleogel-S10 gel and the control gel were identical. The participant received either Oleogel-S10 or control gel for a double-blind study phase of 90 days. The probability that the participant received Oleogel-S10 was 50%, which means that they had a 1 in 2 chance of receiving Oleogel-S10. However, in the follow-up phase of the study all participants were treated with Oleogel-S10 for a period of 24 months. This clinical study was performed at 49 study sites in 26 countries (Argentina, Australia, Austria, Brazil, Chile, Colombia, Czech Republic, Denmark, France, Georgia, Germany, Greece, Hong Kong \[China\], Hungary, Ireland, Israel, Italy, Romania, Russia, Serbia, Singapore, Spain, Switzerland, Ukraine, United Kingdom, and the United States); 223 participants participated in total.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03068780
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Johannes S Kern, MD PhD
Query!
Address
0
0
Melbourne Health
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/80/NCT03068780/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/80/NCT03068780/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT03068780